BioStock: Saniona’s CEO: ”Selectivity is the cornerstone of future epilepsy treatments”
On Tuesday morning Saniona was able to announce advancements in its Kv7-programme. The company has now concluded the lead optimisation phase and the programme moves into the candidate selection phase. Comparable programmes have put peer companies’ valuations in the billions. BioStock contacted CEO Thomas Feldthus to find out more about the news and the programme.
Read the full interview with Thomas Feldthus at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/